FDA Approves 3D Printed Implant for Avascular Necrosis of the Talus
The approval is supported by data from 31 patients and 32 talus replacement surgeries.
General Rheumatology
WellDyne to Provide Physician Access to Scipher Medicine’s PrismRA Blood Test
WellDyne will provide physicians access to Scipher Medicine’s PrismRA test, which identifies RA patients unlikely to respond to TNFi therapy.
FDA Approves Posimir for Postsurgical Analgesia
Posimir is a novel formulation of bupivacaine, an amide local anesthetic, designed to be administered directly into the surgical site.
Kineret Approved for Deficiency of IL-1 Receptor Antagonist
Kineret blocks the biologic activity of IL-1 alpha and beta by competitively inhibiting IL-1 binding to the IL-1 type I receptor.
New Guidelines for the Management of Lyme Disease
The Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology provided new clinical practice guidelines for Lyme disease prevention, diagnosis, and treatment.
FDA to Review AVT02, a High Concentration Biosimilar to Adalimumab
AVT02 is a proposed biosimilar to Humira® (adalimumab) with high concentration (100mg/mL) dosage forms.
No Increased Cardiovascular Risk With Febuxostat vs Allopurinol
In contrast to CARES, FAST found that treatment with febuxostat was not associated with an increase in cardiovascular or all-cause death compared with allopurinol in patients with gout.
Simponi Aria Approved for Polyarticular JIA, Pediatric Psoriatic Arthritis
Simponi Aria is available as a 50mg/4mL strength solution for IV infusion; it is administered as a 30-minute infusion.
Xeljanz Approved for Active Polyarticular Course Juvenile Idiopathic Arthritis
Patients treated with tofacitinib experienced significantly fewer disease flares compared with placebo.
Newly Diagnosed Lupus Erythematosus Could Potentially Be Drug Induced
A new case of cutaneous lupus erythematosus or systemic lupus erythematosus could potentially be drug induced.
